Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

44.84 +1.13 (+2.59%)

Streaming Delayed Price Updated: 11:20 AM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

41 42 Next >

Sanofi's Earnings Outlook ↗

October 24, 2024

Via Benzinga

Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business ↗

October 21, 2024

Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global OTC...

Via Benzinga

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? ↗

October 21, 2024

Let's look beyond this piece of bad news from regulators.

Via The Motley Fool

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer ↗

October 18, 2024

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European...

Via Benzinga

France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block ↗

October 18, 2024

Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 million euros as the French government weighs the sale due to national...

Via Benzinga

Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R ↗

October 15, 2024

France considers blocking Sanofi's $16 billion consumer division sale to U.S. firm CD&R, citing concerns over healthcare sovereignty, job protection, and local production amidst growing political...

Via Benzinga

NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. ↗

October 03, 2024

SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.

Via Chartmill

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice ↗

October 11, 2024

Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...

Via Benzinga

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why ↗

October 10, 2024

Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains ↗

October 07, 2024

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

Via The Motley Fool

Topics Artificial Intelligence

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗

October 04, 2024

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...

Via Benzinga

Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati ↗

October 04, 2024

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes milestone payments and is expected to close by the end of 2024.

Via Benzinga

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses ↗

October 04, 2024

Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...

Via Benzinga

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗

October 01, 2024

HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...

Via Benzinga

Topics Economy

Week In Review: Zenas Raises $259 Million In IPO ↗

September 28, 2024

It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...

Via Talk Markets

Topics Initial Public Offering

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease ↗

September 27, 2024

The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...

Via Benzinga

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗

September 27, 2024

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Via Investor's Business Daily

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs ↗

September 25, 2024

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...

Via Benzinga

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗

September 25, 2024

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...

Via Benzinga

Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

September 24, 2024

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

Via MarketBeat

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences ↗

September 23, 2024

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease.

Via Benzinga

Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval ↗

September 23, 2024

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the...

Via Benzinga

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices ↗

September 20, 2024

FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access...

Via Benzinga

Topics Lawsuit

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows ↗

September 20, 2024

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed...

Via Benzinga

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

September 20, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years ↗

September 18, 2024

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.